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Massive haemoptysis is a life-threatening condition that requires timeous and 
appropriate intervention. Bronchial artery embolisation (BAE) has been advocated as 
initial therapy, in preference over lung resection, in all patients presenting with massive 
and minor haemoptysis. This is despite the relatively high incidence of early recurrence 
of haemoptysis following treatment with BAE. 
 
Though emergency lung resection for active massive haemoptysis has been associated 
with a high mortality, the literature has failed to detail the pre-operative evaluation 
which may have been inadequate and resulted in unsuitable surgical candidates. This has 




Case records from 01 January 2005 to 31 October 2007 of all patients admitted with 
haemoptysis, to the Department of Cardiothoracic Surgery, Inkosi Albert Luthuli Central 
Hospital were reviewed retrospectively and analysed. 
The decision regarding the type of emergency treatment was at the discretion of the 
attending Cardiothoracic Consultant. 
Following clinical examination and basic investigations patients were treated 
accordingly. Those who were haemodynamically stable were discussed at a Consultant 




Group 1 included 281 patients with massive haemoptysis and group 2 included 222 with 
minor haemoptysis. 
Group one 
15 of the 20 patients who were temporised with BAE (75%) had recurrent haemoptysis 
whereas 1 of the 41 patients (2.44%) who underwent lung resection without BAE 
developed recurrent haemoptysis (p-value < 0.0001).  
In patients undergoing BAE and lung resection, there was 1 death and 2 patients 
developed a post resection empyema thoracis (5% mortality; 10% morbidity) compared 
to 2 deaths; 1 post resection empyema thoracis and 1 deep thoracotomy wound infection 
in patients’ undergoing lung resection alone (4.88% mortality; 4.88% morbidity). This 
was not statistically significant (p-value 0.6736). 
 
Group 2 
7 of the 8 patients who were temporised with BAE (87.50%) had recurrent haemoptysis. 
None of the 44 patients who underwent lung resection alone, developed recurrent 
haemoptysis (p-value < 0.0001).  
There were no deaths or surgical complications other than recurrent haemoptysis in 
patients who underwent BAE prior to lung resection.  Though there were no deaths in 
patients who underwent lung resection alone, 2 patients developed a post resection 
bronchopleural fistula and 1 patient developed a post resection empyema thoracis 





These preliminary data suggests that patients presenting with radiologically localised 
disease and massive haemoptysis, who are deemed suitable for surgery, should undergo 
emergency lung resection. This data also suggests that BAE is probably best utilised as a 
temporising measure in patients unsuitable for emergency lung resection.  
This also appears applicable to patients presenting with minor haemoptysis. In this 
scenario however, lung resection may be electively undertaken. 
Furthermore, this study emphasises the need for further prospective studies to clarify 
















At present, bronchial artery embolisation is suggested as the initial form of therapy for 
all patients presenting with haemoptysis (Mal, H., Rullon, I., Mellot, F., Brugière, O., 
Sleiman, C., Menu, Y., and  Fournier, M., (1999); Andrejak, C., Parrot, A., Bazelly, B., Ancel, 
PY., Djibre, M., Khalil, A., Grunenwald, D., and Fartouk, M., (2009);  Shigemura, N., Wan, IY., 
Yu, SC., Wong, RH.,  Hsin, MK., Thung, HK., Lee, TW., Wan, S., Underwood, MJ., and Yim, AP., 
(2009). This includes patients with massive haemoptysis with radiologically localised 
disease who are deemed suitable for lung resection following detailed evaluation thereof. 
Expeditious lung resection in selected patients is curative because it eliminates the risk 
of recurrent haemoptysis since the source of haemoptysis (diseased lung) is removed 
(Knott-Craig, CJ., Oostuizen, JG., Rossouw, G., Joubert, JR., and Barnard, PM., 1993).   
The treatment regarding patients with: a) massive haemoptysis with non-localised 
disease; b) minor haemoptysis with localised disease and c) minor haemoptysis with 
non-localised disease; is also contentious. Therefore, by establishing treatment 
guidelines, based on this clinical review, best practice should be implemented. 
At present, primary therapy for both massive and minor haemoptysis (irrespective of 
feasibility of lung resection) is bronchial artery embolisation (BAE). This may then, be 
followed by lung resection if it is deemed feasible or necessary, (Fernando, HC., Stein, M., 
Benfield, JR., Link, DP., (1998), Knott-Craig et al; Andrejak, C., Parrot, A., Bazelly, B., Ancel, 
PY., Djibre, M., Khalil, A., Grunenwald, D., and Fartouk, M., (2009);  Shigemura, N., Wan, IY., 




BAE is either a temporising or occasionally, definitive intervention.  When BAE is used as 
a temporising measure, followed by non-emergent lung resection (in appropriately 
selected patients), it is thought that this allows sufficient time for adequate resuscitation 
of the patient and clearing of blood from the bronchial tree. This improves lung function 
making lung resection feasible and post-operative complications associated with 
inadequate pulmonary reserve obviated. (Fernando et al; Knott-Craig et al; Andrejak et al; 
Shigemura et al). 
Previous studies have shown a high morbidity and mortality associated with patients 
undergoing emergency surgery for massive haemoptysis (Gourin, A., Garzon, A., (1974). 
However, selection criteria for lung resection were vague and lung isolation techniques 
may have been inadequate.  
Gourin et al had an overall mortality of 17%. When emergency surgery was undertaken 
in patients with active haemoptysis the mortality increased to 33%. However, lung 
isolation techniques were not ideal since 5 of 7 patients, who had spillage of blood into 
the normal bronchial tree, when a double lumen Carlens tube was used, demised. This 
improved when bronchial intubation and balloon catheters were introduced for lung 
isolation. 
In addition, 31 of the 68 patients who underwent lung resection had no evaluation of 
pulmonary function. This is a major pre-operative omission since inadequate lung 
function is a significant predictor of post-operative morbidity and mortality. 
Andrejak et al showed a post-operative morbidity of 71% and mortality of 35% in 
patients undergoing lung resection who were actively bleeding and in whom BAE was 
not undertaken or failed. However, no mention was made of the pre-operative evaluation 
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including pulmonary function tests. This is important since soiling of the airways with 
blood may have occurred in some patients. As a consequence, these patients may have 
had inadequate pulmonary reserve to justify surgery and this would have significantly 
contributed to the high morbidity and mortality. 
 
Other treatment modalities for massive haemoptysis include ice cold saline lavage of the 
airways; instillation of vasoconstrictors into the bronchial tree; cellulose tamponade of 
the bronchi; cavernostomy (patients with cavitatory lung disease with inadequate 
reserve for lung resection, undergo a thoracotomy whereby the lung cavity, which is the 
probable source of the haemoptysis, is surgically opened and packed, usually with 
surrounding muscle); radiotherapy in cases of massive haemoptysis from irresectable 
bronchial carcinoma or instillation of intravenous antifungal agents into mycetoma-
containing cavities of the lung (Jougon, J., Ballester, A., Delcambre, F., Mac Bride, T., Valat, 
P., Gomez, F., Laurent, F., and JF. Velly, JF., (2002) E. Hankanson, E., Kanstantinov, IE., 
Fransson, SG., Svedjeholm, R., (2002); Conlan, A., Hurwitz, S., (1980); Knott-Craig et al; 
Reisz, G., (2005); Haponik, EF., Fein, A., and Chin, R., (2000). These treatment modalities 
involved small cohorts and the results are not significant to warrant their routine use. 
 
Lung resection in the presence of active tuberculosis is thought to be associated with a 
higher complication rate, especially that of bronchopleural fistulae and post-resectional 
empyema thoraces. Therefore, BAE is thought to be the best therapeutic modality in 
patients with massive haemoptysis with active TB, despite being suitable candidates for 
lung resection. These patients, like those with haemoptysis due to sequelar TB, have a 
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high risk of recurrent haemoptysis following BAE. This is despite the fact that there is no 
convincing evidence to suggest that there is a higher incidence of surgical complications 
in patients undergoing emergency lung resection for active massive haemoptysis and 
active TB (Erdogan, A., Yegin, A., Gurses, G., and Demircan, A., (2005) Pomerantz, M., 
(2000); BJ Pomerantz, BJ., JC Cleveland, JC., HK Olson, HK., and M Pomerantz, M., (2001); 
Furak, J., Trojan, I., Szoke, T., Tiszlavicz, L., Morvay, Z., Csada, E., and Balogh, A., (2001); 

















OVERVIEW AND LITERATURE REVIEW 
Massive haemoptysis is life-threatening and an extremely challenging condition that 
requires thorough and timeous intervention. Despite advances in treatment, this 
condition remains a serious threat to the well-being of the patient, since death due to 
asphyxiation and not exsanguination, is not uncommon.  
 
DEFINITION 
Haemoptysis is usually categorised into minor and massive, with massive haemoptysis 
being the major concern. The definition of massive haemoptysis may vary according to 
the quantity of blood expectorated or the clinical condition of the patient. The quantity 
may vary between 600ml to 1000ml in 24 hours, or more than 200ml to 250ml in a 
single bout. It may also include patients who are haemodynamically unstable with a 
haemoglobin <10g/dl, requiring intravenous inotrope infusions or ventilatory support. 
These patients are at high risk of spillage of blood into the normal unprotected lung.  
This is a more functional definition of massive haemoptysis since it necessitates invasive 
intervention to avoid death [Gourin, A et al; Jougon, J et al; Wong, ML., Szkup, P., Hopley, 
MJ., (2002); Andrejak, C., et al.].  
 
Haemoptysis not meeting the above criteria is regarded as minor haemoptysis. 
 
The aetiology of haemoptysis varies in both non-western and western countries. In non-
western countries pulmonary tuberculosis, including tuberculous bronchiectasis is the 
most common cause. In western countries, bronchogenic carcinomas and chronic 
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inflammatory lung diseases due to bronchiectasis and cystic fibrosis are more prevalent. 
Other causes include lung abscess, pneumonia and both cardiac and pulmonary vascular 
abnormalities [Hankanson, E., Kanstantinov, IE., Fransson, SG., Svedjeholm, R., (2002)]. 
 
OUTCOMES 
Massive haemoptysis has an extremely high mortality. Conservative management of 
massive haemoptysis has a mortality of 50-100% [Pomerantz, M., et al; Knott-Craig, CJ., et 
al].  Knott-Craig et al. showed that 36.4% of patients treated medically for massive 
haemoptysis had a recurrent bleed within 6 months. Of these 45% were fatal. No 
patients who underwent lung resection for massive haemoptysis had recurrent 
haemoptysis after 6 months [Knott-Craig, CJ., et al].  
The cause of death is usually asphyxiation and not exsanguination. Mortality rates for 
surgery for massive haemoptysis vary between 7.1% and 18.2% [Knott-Craig, CJ., et al; 
Andrejak, C.; et al] which increases up to 40% when emergency surgery is undertaken 
[Gourin, A., et al; Knott-Craig, CKJ., et al; Andrejak, C., et al; Shigemura, N., et al]. Mortality 
is not affected by the aetiology, activity of TB, lack of therapy, age or sex of the patient 
[Gourin, A., et al]. The most significant factor influencing outcomes is soiling or aspiration 
involving the contralateral normal lung [Gourin, A., et al; Knott-Craig, CJ., et al]. 
 
TREATMENT OPTIONS 
The main treatment modalities include lung resection, bronchial artery embolisation and 
medical therapy. Medical therapy includes anti-tuberculous drug therapy and broad 
spectrum intravenous antibiotics [Erdogan, A., et al; Knott-Craig, CJ., et al]. This form of 
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therapy is usually definitive for minor haemoptysis which is often due to an underlying 
lung infection. 
 
Other treatment modalities include: ice cold saline lavage of the airways; instillation of 
vasoconstrictors into the bronchial tree; cellulose tamponade of the bronchi; 
cavernostomy; radiotherapy for irresectable bronchial carcinoma and instillation of 
intravenous antifungal agents into mycetoma-containing cavities of the lung. 
 
1) SURGERY 
Lung resection is the only definitive form of therapy and is curative [Erdogan, A., et al]. In 
general, due to the high mortality associated with emergency lung resection for active 
massive haemoptysis, surgery is usually undertaken in selected patients if other 
therapies, usually BAE, have failed [Jougan, J., et al; Fernando, HC., et al; Mal, H., et al; 
Knott-Craig, CJ., et al; Andrejak, C.,et al; Shigemura, N.,; et al]. 
Therefore, due to the alarmingly high mortality associated with emergency lung 
resection for massive haemoptysis, a “cooling off” period is suggested. The patient is 
sedated and BAE undertaken to allow clearing of the bronchial tree if soiling of the lungs 
has occurred. This improves the pulmonary reserve and allows adequate resuscitation of 
the patient prior to surgery [Knott-Craig, CJ., et al], which is then usually undertaken 48-
72 hours later.  
All patients presenting with haemoptysis, either electively or as an emergency warrant 
detailed thoracic surgical investigations, prior to deciding on the feasibility of lung 
resection. Those patients presenting with massive haemoptysis require admission to a 
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a) CLINICAL EVALUATION 
The literature regarding the pre-operative nutritional assessment of those patients 
presenting with haemoptysis who require lung resection, is sparse at best. In addition, 
very little is mentioned regarding the analysis of pre-operative investigations to assess 
the feasibility of lung resection. These investigations include routine blood 
investigations, including full blood count (no specific values necessitating blood 
transfusion in this scenario have been cited), renal function and blood coagulation 
studies. Lung function parameters that have been used to permit lung resection in these 
cases include a vital capacity >40% predicted post-operative value and a FEV1 >40% 
predicted post-operative value [Gourin, A., et al]. However other aspects of lung function 
evaluation, including assessing lung parenchymal function and split-lung function 
studies have never been evaluated in this cohort. 
 
b) RADIOLOGY 
Radiological investigations are undertaken to assess the extent of the disease, localise 
the source of the haemorrhage and determine the possible aetiology.  
The chest radiograph is the primary radiographic investigation. Where feasible, high 
resolution computerised tomography (HRCT), which more accurately depicts the extent 
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and location of disease, is undertaken. Lung resection is usually performed after careful 
review of the HRCT.  
 
HRCT depicts five features of underlying lung disease: ground glass appearance, 
consolidation, cysts, nodules and septal thickening. Each feature has a wide differential 
diagnosis. Common conditions include TB, bacterial pneumonia, metastatic carcinoma, 
bronchiectasis and pulmonary oedema. 
Abnormal features of lung disease on chest radiograph include: lung cavitation; 
secondary fungal infection of a lung cavity (ball-in-a hole); bronchiectasis; consolidation; 
bilateral round pulmonary opacities, which according to their size on radiological 
investigations may be termed miliary (1-3mm in diameter), mottling (3mm-5mm in 
diameter) or nodules (greater than 5mm but less than 1cm in diameter).  
 
If a pulmonary arteriovenous malformation (PAVM) is suspected, pulmonary 
angiography is undertaken to confirm the diagnosis, determine the number and location 
of the PAVMs as well as the size and number of the feeding vessels. A pulmonary 
angiogram is also undertaken when the pulmonary artery system is suspected to be the 
source of the haemoptysis. In this instance, haemoptysis is best treated with emergency 
surgery since BAE is futile [Jougon, J., et al; Andrejak, C., et al]. 
However, CT findings may show a specific diagnosis in 50% of patients in whom flexible 
bronchoscopy is non-diagnostic and in 39-88% of patients with a non-diagnostic chest 
radiograph. Localisation of haemoptysis with CT and a chest radiograph is possible in 




In instances of bilateral lobar disease, still within the physiological limits of lung 
resection, the dilemma arises in deciding which lobe to resect. Bronchoscopy, which may 
be either rigid or flexible, may allow localisation of bleeding [Erdogan, A., et al; Jougon, J., 
et al; Hankanson, E., et al; Knott-Craig, CT., et al; Haponik, EF., et al; Shigemura, N., et al]. 
Flexible bronchoscopy requires conscious sedation and thus avoids a general 
anaesthetic. It also allows the bronchoscopist to have a more detailed view of the bronchi 
and permits visualisation of secondary bronchi. This is not possible with rigid 
bronchoscopy [Jougon, J., et al].  
 
Flexible bronchoscopy in patients with massive haemoptysis is certainly not without its 
pitfalls. Blood impairs vision, the airway is never secure, blood clots cannot be easily 
removed and adequate ventilation may require that the flexible bronchoscope be 
removed and replaced by an endotracheal tube. In addition, because this is done using 
conscious sedation, coughing may be provoked which may lead to a catastrophic 
haemorrhage. More importantly, definitive and possible life-saving treatment is delayed. 
Flexible bronchoscopy is efficacious in evaluating central bronchial lesions and is seen as 
a primary method of localising haemoptysis in 49%-92% of patients. The overall 
diagnostic accuracy in evaluating patients presenting with haemoptysis is 10%-43%. 
 
Rigid bronchoscopy usually requires a general anaesthetic.  Using this technique, blood 
clots within the airways are easily removed, the airway is secure and the source of 
haemoptysis is identified. There is no need to visualise the airways distal to the 
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secondary bronchi as lung resection usually involves a lobectomy at best. In addition, in 
the event of active haemoptysis during rigid bronchoscopy, spillage can be prevented by 
wedging the rigid bronchoscope into the main bronchus of the unaffected lung, 
permitting therapeutic procedures (ice-cold saline lavage, cellulose tamponade, 
instillation of vasoconstrictors into the bronchial tree, and insertion of Fogarty catheters 
or bronchus-blockers) to be undertaken. During this time, the airway is secure and the 
patient may be adequately ventilated using the rigid bronchoscope. 
 
SURGICAL TECHNIQUE AND TIMING 
Surgery is usually undertaken following a “cooling off” period. Lung isolation is 
imperative and is usually achieved with either a left or right sided double lumen 
endotracheal tube [Erdogan, A., et al; Haponik, EF., et al].  A left sided double lumen 
endotracheal tube is commonly used since correct placement is more easily obtained 
than a right sided double lumen endotracheal tube.  The bronchial cuff of the double 
lumen endotracheal tube has to be proximal to the upper lobe bronchus to avoid 
occlusion of the upper lobe bronchus which may resultant in inadequate ventilation. The 
distance of the right upper lobe bronchus from the main carina is much shorter than that 
of the left upper lobe bronchus. This makes placement of a right sided double lumen 
endotracheal tube technically more difficult. This is especially important if a left 
pneumonectomy is necessary and the right lung requires ventilation. Insertion of a 
double lumen endotracheal tube is not an innocuous procedure and complications like 
bronchial rupture and malpositon of the endotracheal tube resulting in inadequate 
ventilation and spill can occur. 
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Though not commonly used, a bronchus blocker or a Fogarty catheter is also an effective 
alternative for lung isolation [Hankanson, E., et al]. 
 
Surgery for haemoptysis predominantly involves lung resection (lobectomy; 
bilobectomy or pneumonectomy) and rarely includes cavernostomies and bronchial 
artery ligation.  Cavernostomies are usually performed in instances of lung cavitation 
associated with massive haemoptysis and poor pulmonary reserve. These patients are 
usually not suitable for lung resection and a cavernostomy with cauterisation of the 
bleeding point may stop the haemoptysis. This procedure is usually complicated by a 
bronchopleural fistula, which may require definitive therapy with thoracoplasty. 
 
The commonest cause of haemoptysis in Africa is inflammatory lung disease. This is 
usually due to active tuberculosis or its sequelar form.  The disease process is such that 
the lung firmly adheres to the chest wall, mediastinum and diaphragm. Freeing the lung 
from the thoracic cavity is necessary prior to undertaking lung resection. This may result 
in a significant amount of further blood loss. Therefore, maintaining adequate 
haemostasis during dissection is imperative, especially under circumstances where the 
indication for surgery is blood loss i.e. haemoptysis.   
In instances of ongoing massive haemoptysis, during lung resection, it may be necessary 
to remove the bronchus prior to division of the hilar vessels. This will prevent soiling of 
the contralateral lung in cases of inadequate lung isolation and soiling of the ipsilateral 




COMPLICATIONS OF SURGERY 
Two of the major post-operative complications following lung resection are bronchial 
stump dehiscence and a post-resectional empyema thoracis. Risk factors  may be 
categorised into pre-operative risk factors ( age > 70 years, chronic obstructive 
pulmonary disease, diabetes mellitus, collagen vascular diseases, malnutrition, 
prolonged steroid therapy, induction chemo/radiotherapy, active infection and resection 
through an empyema cavity);  intra-operative risk factors (left pneumonectomy, 
extended or completion pneumonectomy, advanced malignancy, extensive nodal 
dissection, endobronchial disease, inadequate bronchial tissue for closure, residual 
cancer in bronchial stump, long bronchial stump and contamination of the pleural space 
during surgery) and post-operative risk factors(mechanical ventilation and haemothorax 
or empyema).  
 
Muscle flaps, though not essential to prevent bronchial stump dehiscence, have been 
advocated in instances of pre-operative sputum positivity, the presence of a 
bronchopleural fistula prior to surgery, polymicrobial space contamination and 
anticipated space problems following lobectomy [Pomerantz, M.; Pomerantz, BJ., et al; 
Furak, J., et al].  Antibiotics (anti-TB therapy) should be continued for at least 12 to 24 
months post surgery depending on bacteriologic and radiologic findings. If the 
antibiotics are stopped too soon, this may exacerbate resistance or increase 
mycobacterial spread [Pomerantz, M., et al].  
Though there are variations in surgical techniques for bronchial stump closure i.e. staple 
versus suture closure, no comparative trials have been undertaken to show the 
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superiority of either. However, meticulous suture technique and preservation of the 
blood supply to the bronchial stump by minimising skeletonisation of the bronchial 
stump, helps prevent a bronchopleural fistula. 
 
Post-resectional empyema thoracis is another fairly common complication occurring in 
about 13-45% of cases. The patient then requires a prolonged period of drainage and 
sterilisation of the pleural space and possibly further definitive surgical procedures in 
the form of either open drainage or thoracomyoplasty. The problem of a residual pleural 
space following lobectomy may be resolved intra-operatively by undertaking a 
myoplasty or a tailoring thoracoplasty. 
 
Lung resection in the presence of active tuberculosis was associated with a high 
morbidity and mortality.  Lung resection in the presence of active TB was thought to be 
associated with a morbidity of up to 12.5% and mortality of 5.5% [Mouroux, J., et al].  
Furak, J., et al, reported morbidity rates of 22.9% in patients with active tuberculosis 
who underwent lung resection.  Active tuberculosis is a risk factor for post lung resection 
empyema thoracis and bronchopleural fistulas. As such, lung resection for patients with 
active tuberculosis is recommended in instances, where feasible, for MDR TB or massive 
haemoptysis. As a consequence, patients presenting with haemoptysis with either 
confirmed or suspected active tuberculosis were treated definitively with BAE. However, 
patients with MDR TB who underwent lung resection after a minimum of 3 months of 
medical therapy were not always sputum negative at the time of surgery. Despite this, 
there was no evidence to show a higher surgical complication rate [Pomerantz, M.; 
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Pomerantz, BJ., et al; Furak, J., et al; Mouroux, J., et al].  In fact, the current approach is to 
adopt a more aggressive strategy for MDR TB.  This follows the findings that in patients 
with MDR TB, early surgery in combination with medical therapy achieves higher cure 






















2) BRONCHIAL ARTERY EMBOLISATION 
Bronchial artery embolisation (BAE) has become an important temporising and 
occasionally, definitive form of therapy for haemoptysis. Due to poor pulmonary reserve 
and other medical comorbid conditions most patients are not surgical candidates 
[Andrejak, C., et al]. BAE is effective in preparing patients for elective rather than high 
risk emergency surgery [Fernando, HC., et al; Knott-Craig, CJ., et al; Andrejak, C., et al; 
Shigemura, N., et al.]. 
 
TECHNIQUE 
Massive haemoptysis usually occurs from the bronchial arteries (90%); pulmonary 
circulation (5%) and the rest (5%) from the aorta (e.g. aortobronchial fistula, ruptured 
aortic aneurysm) or the systemic arterial supply to the lungs (other than the bronchial 
arteries). 
 
As a consequence of underlying parenchymal lung disease, particularly that of 
inflammatory lung disease, pulmonary circulation is decreased or occluded at the level of 
the pulmonary arterioles due to hypoxic vasoconstriction, intravascular thrombosis and 
vasculitis. Bronchial arteries then proliferate and enlarge to replace the pulmonary 
circulation. These arteries occur in an area of inflammation and are prone to rupture due 
to erosion by bacteria or elevated regional blood pressure [Jougon, J., et al]. The arterial 





BAE is a transcatheter technique, using the Seldinger technique to gain access into the 
femoral arteries in order to embolise the arterial source of haemoptysis [Mal, H., et al]. 
Arteries, other than the bronchial arteries that may be the source of the haemoptysis 
include: the intercosto-brachial trunk, subclavian artery, axillary artery and the internal 
mammary artery [Wong, ML., et al]. Embolic agents include gelfoam, polyvinyl alcohol 
particles, isobutyl cyanoacrylate, absolute alcohol and steel coils or steel spirals.   
 
This procedure does not require a general anaesthetic but has to be undertaken in 
haemodynamically stable patients without active massive haemoptysis at the time of the 
procedure. The success rate of BAE ranges from 64 – 100% [Mal, H., et al; Shigemura, N., 
et al].  Recurrence usually occurs in the first 6 months in 20 -25% of patients which is 
due either to incomplete occlusion of the feeding vessels, recanalisation of previously 
embolised vessels, the development of new collaterals or inadequate treatment of the 
underlying pulmonary disease [Fernando, HC., et al; Mal, H., et al; Hankanson, E., et al]. 
The consequence of recurrent massive haemoptysis may be catastrophic. Death due to 
recurrent massive haemoptysis in patients who have undergone BAE, who are in the so 
called ‘’cooling off period’’ and in whom lung resection is feasible, is unacceptable.   
 
Repeat embolisation may be successful in those with recurrence. Failure to embolise 
bronchial vessels occurs in 13% due to non-bronchial artery collaterals [Mal, H., et al; 
Valipour, A., Kreuzer, A., Koller, H., Koessler, W., and Burghuber, OC., (2005]. Complications, 
though uncommon, include spinal cord syndromes, bronchial stenosis, 
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bronchoesophageal fistulas, bronchial infarction and transient cortical blindness [Wong, 
ML., et al].   
 
ANATOMY OF THE BRONCHIAL ARTERIES 
Bronchial arteries supply the trachea, extra- and intrapulmonary airways, 
bronchovascular bundles, nerves, regional lymph nodes, visceral pleura, oesophagus and 
the vasa vasorum of the aorta, pulmonary artery and pulmonary vein. 
Bronchial artery anatomy varies in origin, branching pattern and course. They originate 
directly from the descending thoracic aorta, usually between T5 and T6 vertebrae. Four 
classical branching patterns include: (i) two on the left and one on the right that 
represents an intercostobronchial trunk (ICBT)-40% of cases; (ii) one on the left and one 
ICBT on the right-21% of cases; (iii) two on the left and two on the right (one ICBT and 
one bronchial artery)-20% of cases; (iv) one on the left and two on the right (one ICBT 
and one bronchial artery)-10% of cases. 
The right ICBT is most consistently seen on angiography (80% of patients) and usually 
arises from the right posterolateral aspect of the thoracic aorta. The right and left 
bronchial arteries arise from the anterolateral aspect of the thoracic aorta and the 
occurrence of both originating as a common trunk at angiography is rare. 
Bronchial arteries originating outside of T5 and T6 vertebrae at the level of the major 
bronchi are anomalous and range from 8.3% to 35%. It may arise from the aortic arch, 
internal mammary artery, thyrocervical trunk, subclavian artery, costocervical trunk, 




Non-bronchial systemic collateral vessels enter the pulmonary parenchyma through the 
adherent pleura or via the pulmonary ligament. In addition these arteries do not course 
parallel to the bronchi.  
 
Aberrant bronchial arteries can be distinguished anatomically and angiographically from 
non-bronchial systemic collateral vessels in that they extend along the course of the 
major bronchi and most originate from the aortic arch. It is usually present when a 
significant bronchial arterial supply to areas of abnormal pulmonary parenchyma is not 
demonstrated during angiography. Bronchial arteries of anomalous origin should be 
considered in patients with recurrent haemoptysis despite successful embolisation and 
in patients with parenchymal lung disease where the source of bleeding has not been 
detected. 
 
Dorsal and ventral radicular spinal arteries arise from segmental spinal arteries and 
supply the dorsal and ventral roots. About eight anterior medullary arteries reinforce the 
anterior spinal artery which is the major source of spinal cord perfusion. The artery of 
Adamkiewicz, or greater anterior medullary artery, reinforces the circulation of lumbar 
enlargement of the spinal cord. This unilateral vessel has been observed to arise between 
T9 and T12 in 75% of cases.   
 
Anterior medullary arteries have a characteristic "hairpin" configuration at angiography. 
Radicular arteries are often visualized during BAE.  Unintentional embolisation of 
radicular arteries does not appear to cause clinical problems like spinal cord ischemia. 
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Therefore the presence of radicular arteries is not a contraindication for BAE. Anterior 
medullary arteries are rarely observed, but embolisation and repeat angiography should 
be avoided because spinal cord ischemia may occur with embolisation. Spinal arteries 
may arise from the intercostal branch of the right ICBT in 5%–10% of cases.  
 
Normal adult bronchial arteries measure less than 1.5mm in diameter at their origin and 
0.5mm at their point of entry into a bronchopulmonary segment. Bronchial arteries 
larger than 2mm at CT scan are usually abnormal. Contrast enhanced CT scans show 
hypertrophied bronchial arteries as enhancing nodular or tubular structures within the 
mediastinum and around the central airways, usually located in the retroesophageal 
area, retrotracheal area, retrobronchial area, posterior wall of the main bronchus and 
aortopulmonary window. Mediastinal lymph nodes, the azygous vein, and an enhancing 
oesophageal wall can mimic the bronchial arteries on CT scan. 
 
The number and origin of the bronchial arteries are carefully evaluated to determine the 
optimal approach for embolisation. A thoracic aortogram is usually undertaken and is 
also useful to detect non-bronchial systemic arteries that supply pathological areas of the 
lung. 
 
Cobra-type curved catheters are most commonly used for catheterisation of the 
bronchial artery. Other catheters include Simmons-1, Headhunter and the Yashigo-type. 
Microcatheters allow superselective catheterisation of vessels. This allows safe 
positioning of the catheter within the bronchial circulation, beyond the origin of the 
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spinal cord branches which helps prevent disastrous neurological complications. After 
catheterisation of the bronchial artery, bronchial angiography is performed with manual 
injection of contrast medium.  
 
RADIOLOGICAL FEATURES OF THE CULPRIT VESSELS CAUSING HAEMOPTYSIS 
Angiographic features of the blood vessels causing massive haemoptysis include 
hypertrophied and tortuous bronchial arteries, neovascularity, hypervascularity, 
shunting into the pulmonary artery or vein, extravasation of contrast medium, and 
bronchial artery aneurysms [Fernando, HC., et al].  Although extravasation of contrast is 
considered a specific sign of bronchial bleeding, this finding is rarely seen, and its 
reported prevalence ranges from 3.6% to 10.7%.  Thus, determining which arteries are 
to be embolised should be based on a combination of the CT scan, bronchoscopy, 
angiography and clinical correlation.  All angiograms, including intercostal arteriograms, 
must be carefully scrutinised for opacification of spinal arteries to avoid inadvertent 
embolisation.  
 
MATERIALS FOR EMBOLOTHERAPY 
Numerous embolic materials are used for BAE.  Absorbable gelatin sponge is widely used 
because it is inexpensive, easy to handle, and has a controllable embolic size. 
Disadvantages are its resolvability and lack of radiopacity. Its use may lead to 
recanalisation of the embolised artery and may sometimes be responsible for recurrent 
bleeding. Polyvinyl alcohol particles are nonabsorbable embolic materials, ranging from 
350–500 µm in diameter and are the most frequently used materials. Its use may prevent 
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the early recurrence of haemoptysis due to recanalisation of the embolised artery [Wong, 
ML., et al]. 
 
It is essential to avoid the use of embolic materials that can pass through the 
bronchopulmonary vascular network which is usually about 325 µm in the human lung. 
Pulmonary infarction via bronchial artery–pulmonary artery shunts or systemic artery 
embolisation via bronchial artery–pulmonary vein shunts may occur when embolic 
agents less than 325 µm in diameter are used. It is important to avoid using embolic 
agents that produce distal occlusion to such an extent, that normal peripheral branches 
supplying the bronchi, oesophagus, or vasa vasorum of the pulmonary artery or aorta 
become occluded. This may lead to disastrous complications like bronchial, oesophageal, 
pulmonary arterial, or aortic wall necrosis. To avoid these complications, the use of 
polyvinyl alcohol particles with a diameter of 350–500 µm is recommended for BAE.  
 
Liquid embolic agents like isobutyl-2 cyanoacrylate and absolute ethanol are not 
currently used because of the high risk of severe complications such as tissue necrosis. 
Stainless steel platinum coils are generally not used for BAE because they tend to occlude 
more proximal vessels and may preclude repeat embolisation if haemoptysis recurs. 
However, they may be used to occlude a pulmonary artery aneurysm and may 
occasionally be used in the internal mammary artery to prevent embolisation of a normal 





RESULTS OF BAE 
BAE has been shown to be effective in controlling acute massive haemoptysis. The initial 
non-recurrence rates for BAE have been reported to be 73%–98% [Mal, H., et al], with a 
mean follow-up period ranging from 1 day to 1 month. As a consequence of the 
introduction of superselective embolisation and the refinement of embolic agents and 
techniques the immediate success rate of BAE has improved. However, the long-term 
success rate is still poor. Long-term recurrence rates have been reported to be 10%–
52%, with a mean follow-up period ranging from 1 to 46 months.  BAE is a palliative or 
temporising procedure that prepares the patient for elective surgery. However, it may be 
regarded as definitive in patients treated medically. 
 
COMPLICATIONS OF BAE 
Recurrent bleeding may be caused by recanalisation of embolised vessels, incomplete 
embolisation, revascularisation by the collateral circulation, inadequate treatment of the 
underlying disease, progression of the underlying lung disease or non-bronchial 
systemic arterial supply. Recurrence rates may also be influenced by the cause of the 
haemoptysis. Recurrent bleeding is more common in patients with chronic tuberculosis, 
aspergillomas, or neoplasms [Mal, H., et al]. Neoplasms receive its blood supply from 
multiple feeder vessels other than the bronchial artery and aggressively invade the 
bronchial vasculature.  
 
Complications of BAE include chest pain (24%-91%), which is usually transient and is 
likely related to an ischaemic phenomenon caused by embolisation; dysphagia due to 
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embolisation of oesophageal branches (0.7%-18.2%) which usually regresses 
spontaneously; subintimal dissection of the aorta or the bronchial artery during BAE 
which occurs in 1%–6.3% of patients and is usually asymptomatic. The most disastrous 
complication of BAE is spinal cord ischemia due to the inadvertent occlusion of spinal 
arteries [Mal, H., et al]. The prevalence of spinal cord ischemia after BAE is reported to be 
1.4%–6.5%.  The visualisation of radicular branches on bronchial or intercostal 
angiograms is not an absolute contraindication for BAE. However, when the anterior 
medullary artery (artery of Adamkiewicz) is visualized at angiography, embolisation 
should not be performed.  
 
Other rare complications that have been reported in the literature include aortic and 
bronchial necrosis, bronchoesophageal fistulae, non–target organ embolisation (e.g., 
ischemic colitis), pulmonary infarction, referred pain to the ipsilateral forehead and orbit 
and transient cortical blindness. It is postulated that cortical blindness develops because 
of embolism to the occipital cortex, either via a bronchial artery–pulmonary vein shunt 
or via collateral vessels between the bronchial and vertebral arteries.  
Non-bronchial systemic arteries can be a significant source of massive haemoptysis, 
especially in patients with pleural disease from extension of the underlying lung disease. 
Missing the non-bronchial systemic arteries at initial angiography may result in early 
recurrent bleeding after successful embolisation of the bronchial arteries [Mal, H., et al]. 
In the presence of pleural thickening, non-bronchial systemic feeder vessels that 
originate from various arteries e.g. intercostal artery, branches of the subclavian and 
axillary arteries, internal mammary artery and the inferior phrenic artery may develop 
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along the pleural surface and become enlarged as a result of the inflammatory process. 
Pleural thickening seen on the plain chest radiograph negatively influences the long-term 
success rate of BAE. Following BAE, Wong et al. noted that 75% of patients had recurrent 
haemoptysis as an inpatient when bleeding occurred from non-bronchial systemic 
arteries and only 8% recurrence when the bronchial arteries were the source.  Mal et al. 
assessed immediate and long term success of BAE for massive haemoptysis and showed 
an immediate success rate of 77% (43 of 56 patients). Long term control of bleeding 
(beyond 3 months) was achieved in 45% (25 of 56 patients). 
CT may help predict the presence of non-bronchial systemic collateral vessels as a source 
of bleeding in patients with massive haemoptysis. Pleural thickening of more than 3mm 
and tortuous enhancing vascular structures within hypertrophic extrapleural fat seen on 
contrast-enhanced CT are suggestive of non-bronchial systemic arterial supply in 
patients with massive haemoptysis. Use of CT to predict the presence of significant non-
bronchial systemic vessels resulting in haemoptysis may help in localising the site of 











3) MEDICAL THERAPY 
Conservative medical therapy using antibiotics is used to prevent further haemorrhage 
by preventing progression of disease [Erdogan, A., et al]. In Africa, haemoptysis is usually 
caused by inflammatory lung disease which includes tuberculosis (including its 
sequelae), lung abscess and bronchopneumonia. The organisms commonly responsible 
include; anaerobes (bacteroides species and fusobacterium nucleatum), gram-positive 
bacteria (staphylococcal species, streptococcal species and haemophilus influenza) and 


















OTHER TREATMENT MODALITIES 
Life-threatening active massive haemoptysis may be treated using endobronchial 
therapies aimed at causing vasoconstriction of the bronchial arteries. Though not 
commonly used, these therapies may be useful when other modalities fail or are not 
feasible [Reisz, G., (2005); Andrejak, C., et al].  The arteries responsible for haemoptysis 
are similar to systemic arterial vessels in that the mural musculature is vasoresponsive, 
the exception being the pulmonary artery or its branches. Therefore, therapies causing 
vasoconstriction, decrease blood flow within these vessels causing thrombotic occlusion 
of the breached distal vessels. 
 
a) ICE COLD SALINE LAVAGE 
Rigid bronchoscopy and lavage of the bleeding lung is one such technique causing 
vasoconstriction of the culprit vessels. This is usually used as an emergency procedure 
where other treatment modalities have been unsuccessful or are not suitable [Conlan, A., 
Hurwitz, S., (1980); Knott-Craig, CJ., et al; Reisz, G.,].  
Occasionally, this procedure has been used to stop haemoptysis and stabilise the patient 
prior to undertaking definitive therapy. A general anaesthetic is required. A rigid 
bronchoscope is introduced into the main bronchus of the non-bleeding side. This 
protects the underling lung from spillage and in addition allows ventilation with 100% 
oxygen. Thereafter, the bronchoscope is placed into the main bronchus of the 
pathological lung in order to evacuate blood clots and irrigate the airways with cold 
normal saline (4°C) in 50ml aliquots. This is then suctioned after about 30 seconds to a 
minute, the normal side re-intubated with the rigid bronchoscope and ventilation 
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continued. As bleeding slows, localisation of the haemorrhage from the airways is 
possible. On average, 500ml of normal saline is used to stop all bleeding. 
 
b) VASOPRESSORS 
Bronchial lavage using vasopressors (epinephrine; 1% adrenalin-saline solution) have 
also been used in an attempt to staunch haemoptysis. This is usually done after the blood 
clots have been removed from the airways and the haemoptysis has ceased with the use 
of ice cold saline lavage. This procedure cannot be undertaken with active bleeding since 
the vasopressor will not penetrate the site of haemorrhage because it will be diluted and 
flushed away by the blood.  
Other pharmacological methods causing vasoconstriction of the bronchial arteries 
include intravenous vasopressin or aerosolised adrenalin. However, if these methods are 
used prior to undertaking BAE, there is a higher occurrence of technical failure because 
the offending arteries (bronchial or non-bronchial collateral arteries) undergo 
vasospasm which makes engaging these vessels, even with the microcatheters, more 
difficult. 
 
The pulmonary artery wall is thin and is not as sensitive to vasoconstrictors as the 
bronchial arteries. Therefore, the methods described above to stop haemorrhage, will 
not be effective if haemoptysis occurs from the pulmonary arteries [Jougon, J., et al]. 
Bleeding from these vessels usually occur from ulceration of the vessel wall due to 
destruction from inflammation or malignancy. In this instance, haemorrhage is usually 
stopped by clot formation over the vascular tear. When the clot lyses or the tear 
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progressively enlarges, fatal haemorrhage may occur. Surgery in this instance is curative. 
Distinguishing bronchial from pulmonary artery haemorrhage is difficult. Clues inferring 
pulmonary artery haemorrhage include: radiological studies showing a fungal ball, lung 
abscess and a cavity that empties and refills. 
 
c) ELECTROCAUTERY 
Laser YAG electrocautery used when haemoptysis is due to carcinoma invading the 
airways is also undertaken with rigid bronchoscopy [Jougon, J., et al]. This is done once 
the bleeding has stopped through the use of other endobronchial control measures. 
 
d) MECHANICAL TAMPONADE 
The main or segmental bronchi on the side of the haemorrhage may be occluded using a 
topical haemostat, a double lumen endotracheal tube, fogarty catheter or a bronchus 
blocker [Reisz, G. et al,] to tamponade the haemorrhage. 
Bronchoscopic guided topical haemostatic tamponade using oxidised regenerated 
cellulose mesh (ORC) has occasionally been used to successfully stop massive 
haemoptysis when other endobronchial therapies are unsuccessful [Valipour, A., et al]. 
This agent induces clot formation and tamponades bleeding.  
A general anaesthetic and rigid bronchoscopy is undertaken to identify the site of 
haemorrhage. A flexible bronchoscope is then inserted through the rigid bronchoscope 
and the site of bleeding confirmed. Using a grasping forceps through the flexible 
bronchoscope, the mesch is placed as peripheral as possible into the bleeding bronchus. 
The mesch conforms and adheres to the airways and tamponades bleeding from the sub-
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segmental to lobar bronchus level. Usually 4 to10 layers of mesh are used to effect 
treatment and formation of thrombus. ORC has good tissue compatibility, is bactericidal 
and has a low incidence of promoting foreign body reaction. It is absorbed within 7 to 20 
days, usually without evidence of a foreign body reaction. 
Complications of this procedure include an obstructive bronchopneumonia, especially 
with tamponade of a lobar bronchus but this usually resolves with antibiotic therapy. 
 
Lung isolation using a double lumen endotracheal tube, fogarty catheter or bronchus 
blocker may also be used to salvage patients with active massive haemoptysis in whom 
first-line treatment modalities have failed. Once the site of haemorrhage is confirmed, 
lung isolation using the above methods may be used to maintain patency of the airways 
and control bleeding. The affected lung is isolated whilst the unaffected lung is 
adequately ventilated [Erdogan, A., et al; Hankanson, E., et al; Knott-Craig, CJ., et al; 
Haponik, EF., et al].  
 
A double-lumen endotracheal tube may be used in severe cases of massive haemoptysis 
where urgent control of the airways is critical in order to prevent asphyxiation. However, 
placement can be challenging and the tube may easily be dislodged. This may lead to 
aspiration and death. In addition, blood clots causing airway obstruction cannot be easily 
removed with a flexible bronchoscope placed through the double lumen tube. 
 
Fogarty catheters and bronchial blockers are easily placed (even at a segmental level) 
and are effective in tamponading bleeding. However, they are also easily dislodged and 
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complications include a post-stenotic pneumonia due to atelectasis of the occluded lung 
[Hankanson, E., et al]. 
 
Surgery for massive haemoptysis in appropriately selected patients has been accepted to 
be curative and the best modality of therapy for these patients. However, the timing of 
surgery is imperative. The general trend in these cases appears to favour BAE as a 
temporising measure prior to emergency lung resection since the mortality and 
morbidity is alarmingly high in patients who are actively bleeding at the time of surgery. 
This is most likely due to spillage and soiling of the normal bronchial tree resulting in 
inadequate ventilation. However, BAE commonly fails and often patients with adequate 
pulmonary reserve prior to BAE, have a repeat massive bout of haemoptysis, aspirate 
and may demise from asphyxia or become ineligible for lung resection now as a 
consequence of poor pulmonary function. 
As the techniques for lung isolation and ventilation have improved, together with a more 
thorough and detailed pre-operative patient evaluation for lung resection, it stands to 
reason that the risks associated with this type of surgery would have diminished as well. 
However, this has never been appropriately evaluated. Instead, BAE has always been 
considered first-line therapy despite the risk of recurrent massive haemoptysis which 
can be fatal.  
 
Patients presenting with minor haemoptysis have also been treated with BAE as first-
line therapy. No previous studies have compared medical therapy to BAE or to lung 
resection for that matter. Therefore, case records of patients presenting with 
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haemoptysis (minor and massive) have been reviewed. Patients were treated either with 
medical therapy, BAE or lung resection as first-line therapies. Recurrent haemoptysis 
and procedural complications following one of the first-line treatment modalities will be 
regarded as treatment failure. 
In view of the high risks associated with surgery for active massive haemoptysis, lung 
resection has not been contemplated even in suitable candidates. This should be 
challenged, since it is reasonable to assume that lung resection may be undertaken as a 
first-line treatment modality in appropriately selected patients, especially in an 
emergency. 
Hence, a new protocol may be established, particularly regarding the indication for BAE 
















To compare the composite outcome of mortality, recurrent haemoptysis and procedural 
morbidity between surgery alone versus BAE plus surgery in patients who are amenable 




To suggest a treatment protocol for patients with haemoptysis based on the preliminary 















Emergency lung resection without BAE is the optimal treatment strategy in 
appropriately selected patients presenting with massive haemoptysis. 
 
Elective lung resection without BAE is the optimal treatment strategy in appropriately 



















MATERIALS AND METHODS 
Authorisation to access and review case records from 01 January 2005 to 31 October 
2007 of all patients admitted with haemoptysis, to the Department of Cardiothoracic 
Surgery, Inkhosi Albert Luthuli Central Hospital and King George V Hospital, was granted 
by the Superintendants of each institution. 
The decision regarding the type of emergency treatment was at the discretion of the 
attending Cardiothoracic Consultant. Patients, who were haemodynamically stable and 
not actively haemorrhaging, were discussed at a consultant forum and treatment was 
based on consensus.  
 
All patients with active haemoptysis, or a history thereof, were included in the study and 
patients with other sources of bleeding mimicking haemoptysis e.g. haematemesis or 
bleeding from the upper airways, were excluded. 
 
Depending on the quantity of haemoptysis, patients were grouped into either those 
presenting with massive or minor haemoptysis. 
Each of the two groups was further subdivided according to the type of treatment 
undertaken, viz.  
 a) Surgery  
  i) Temporised with BAE and  
  ii) no BAE   
 b) Definitive BAE  
 c) Medical therapy 
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A detailed history and examination was undertaken on all patients as a preliminary 
assessment of determining, not only the possible aetiology of the haemoptysis, but also 




Haemoptysis requires a detailed history and physical examination to establish the 
urgency of treatment. Important information required includes: quantity of blood 
expectorated, date of occurrence (especially if massive),  number of episodes, reliable 
witnesses (health care professional),  a history of blood transfusions as a consequence of 
haemoptysis, , previous episodes of haemoptysis and treatment thereof (inpatient or 
outpatient, BAE, surgery or medical).  
 
Since tuberculosis is endemic in South Africa, it is not surprising that it is a major cause 
of haemoptysis in our patient population. Subsequently, a detailed history regarding 
tuberculosis is also imperative because this may impact on the type and timing of 
treatment. Further details include: if and how the diagnosis of TB was established, 
treatment regimen, treatment compliance, TB sensitivities, previous thoracic surgery for 
TB and the number of recurrences of TB.  
 
The prevalence if HIV in sub-Saharan Africa is the highest in the world. Therefore, it was 
necessary to counsel patients to obtain consent regarding voluntary testing (where 
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necessary), information about their HIV status, anti-retroviral therapy, their current CD4 
cell count and viral load if available.  
 
The grade of the patient’s effort tolerance (MRC-modified medical research council 
dyspnoea scale) was used as a crude assessment of pulmonary function.  An effort 
tolerance greater than 2 was suggestive of impaired pulmonary function. This was used 
in association with more accurate methods of assessing pulmonary function in order to 
determine the feasibility of lung resection. Cardiac causes of dyspnoea were also 
excluded. 
 
A careful review of the patient’s symptoms and medical history may assist in 
determining the possible aetiology of haemoptysis. Common causes include:  
i) inflammatory lung disease (usually tuberculosis or its sequelar forms –      patients 
may present with an established diagnosis of active tuberculosis, constitutional 
symptoms or a history of previous tuberculosis) 
 ii)  pulmonary artery venous malformation-PAVM (history and examination may  
 include a family history of a PAVM, epistaxis, cyanosis and a machinery  
 murmur) 
iii)   bronchial or metastatic carcinoma (history may include an established diagnosis of 







This was an important part in the preliminary evaluation for lung resection. Important 
features on clinical examination included pallor (this may be an indication of chronic 
disease or severity of haemoptysis), temporal wasting (suggests poor nutrition), 
lymphadenopathy (scalene lymph nodes in the presence of bronchial carcinoma may 
indicate metastatic disease) and features of AIDS (generalised wasting and 
lymphadenopathy, oral thrush, etc.). 
 
The respiratory and cardiovascular systems were examined for pertinent features to 
help in the assessment of both the severity of the haemoptysis and the extent of 
underlying lung disease. These features included: the oxygen saturation (using a pulse 
oximeter), respiratory rate, pulse and blood pressure and other features suggestive of 
hypovolaemia as a consequence of blood loss (decreased Glasgow coma scale, cool 
peripheries and decreased urine output). 
 
INVESTIGATIONS 
The timing of investigations depends on the severity of the haemoptysis and the patient 
haemodynamics. Massive haemoptysis requires emergency investigations.   
 
Blood investigations included:  
i) Arterial blood gas   
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 A PaO2 >60mmHg and PaCO2<45mmHg were usually the lower limits for lung 
resection. Blood gas analysis was also useful in assessing the risk of post-lung 
resection mechanical ventilation. 
 
ii) Full blood count   
A haemoglobin >10g/dl was usually necessary in patients with massive 
haemoptysis. Indicators of acute blood loss and chronic disease may also be seen 
on analysis. 
 
iii) Clotting profile 
This usually was normal but if not, treatment to correct this was undertaken 
prior to surgery or bronchial artery embolisation. 
 
iv) Liver function and renal function 
 Patients suitable for surgery usually had an albumin>30g/dl (this was suggestive 
of adequate nutrition) and all patients should ideally have normal renal 
 function. BAE requires contrast which is nephrotoxic and lung resection 
undertaken in patients with renal impairment is associated with a higher risk of 
post-operative morbidity and mortality.  
 
v) HIV 
The HIV status was usually only considered when lung resection for haemoptysis 
was elective and not life-saving (as in cases of active massive haemoptysis). 
43 
 
Currently, the Department of Cardiothoracic Surgery UKZN unit policy regarding 
surgery for HIV positive patients states that, patients with a CD4 cell count >200 
cells/ul or an undetectable viral load in patients on anti-retroviral therapy, are 
suitable for surgery, provided other criteria for lung resection is satisfactory. 
 
vi) Pulmonary function tests 
This was only undertaken in patients who did not have active haemoptysis. Lung 
resection was usually undertaken when the ppoFEV1>40% and if necessary, a 
ppoDLCO>40% (ppo: predicted post-op FEV1: forced expiratory volume in the 
first second; DLCO: diffusing capacity for carbon monoxide). 
 
vii) Radiology 
A chest radiograph and HRCT of the chest (if feasible) was undertaken in all 
patients presenting with haemoptysis. These radiological investigations allow 
assessment of the extent of disease, possible aetiology and feasibility of lung 
resection. Following radiological review, localised lung disease was regarded as 
lung disease less than, or equivalent to, one lung. It stands to reason then that, 
extensive bilateral lung disease was lung disease greater than the extent of one 
lung.  
 






Following detailed clinical evaluation, patients may require resuscitation. This may 
necessitate judicious fluid therapy with blood if necessary, oxygen supplementation, 
airway protection (using a double lumen endotracheal tube, usually in patients with 
active massive haemoptysis) and mechanical ventilation.  Depending on the possible 
aetiology of haemoptysis, anti-TB therapy and broad spectrum intravenous antibiotics 
were usually commenced. 
Thereafter, definitive treatment was undertaken based on the amount of haemoptysis, 
extent of lung disease, arterial blood gas, albumin, CD4 count, viral load and pulmonary 
function tests. Lung resection was undertaken in the presence of localised disease and if 
surgery was deemed suitable following detailed evaluation.  
 
BAE was undertaken either as a temporising measure in those patients suitable for lung 
resection or as definitive therapy in patients declining surgery or who were deemed 
unsuitable for surgery. The decision regarding temporising surgical patients using BAE 
was at the discretion of the Consultant Cardiothoracic Surgeon on duty. 
 
BAE was undertaken emergently by the on-call radiologist.  Since the incidence of pleural 
disease is high in our patient population and if no contraindication exists, both bronchial 
and non-bronchial sources of haemoptysis are embolised. A pan-aortic radiological 
review to evaluate the culprit vessels was usually undertaken.  
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Unless suspected, no attempt was routinely made to assess for a possible pulmonary 
artery source of the haemorrhage. Polyvinyl alcohol sponges were the most commonly 
used materials for embolotherapy.  
 
Patients with massive haemoptysis suitable for lung resection underwent surgery either 
emergently or urgently.  Those with minor haemoptysis underwent elective surgery on 
the same admission. 
 
Medical therapy alone was administered to all patients not suitable for surgery and/or 
BAE, those who refused surgery and/or BAE or had minor haemoptysis as a consequence 
of a specific aetiology which was then treated accordingly. 
 
Recurrent haemoptysis and the complications of each modality of therapy was analysed 
in all patients prior to discharge.  Where possible, patients were followed up at the out-
patient thoracic clinic and their symptoms reviewed.  
 
Patients who underwent lung resection were followed up for at least 1 month from their 
date of discharge. The other groups of patients’ were followed up for a period of at least 
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(n=84) 
















HIV    
positive 







































 p- value 
Recurrent 
Haemoptysis 
1 15 <0.00001 
Protocol 
Morbidity 
2 2 0.5915 
Mortality 2 1 1.0000 
All complications 5 18 <0.00001 
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0 7 <0.00001 
Protocol Morbidity 3 0 1.0000 
Mortality 0 0 1.0000 
All complications 3 7 <0.00001 
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2 3 7  
Left 
pneumonectomy 
10 3 11 2 
Right upper 
lobectomy 
8 4 7 3 
Left upper 
lobectomy 
14 6 13 3 
Right lower 
lobectomy 
3 1 3  
Left lower 
lobectomy 
2  1  
Right upper and 
middle 
lobectomy 
1 1 1  
Middle 
lobectomy 
 1   
Middle and right 
lower lobectomy 
1 1   
Other   1  
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ALL RECURRENT HAEMOPTYSIS 
RISK FACTOR OR 95% CI p-value 
BAE and Surgery vs 
Surgery alone 
457 31-6651 <0.001 
HIV positive 







COMPLICATIONS OF BAE AND MEDICAL THERAPY 
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Results of the subgroups analysed were based on the intention to treat. 
 
GROUP 1: MASSIVE HAEMOPTYSIS 
a) SURGERY 
An analysis comparing the occurrence of recurrent haemoptysis following treatment, 
morbidity, mortality and all complications (including recurrent haemoptysis, morbidity 
and mortality) between those patients temporised with BAE prior to surgery and those 
treated with surgery alone using the Fischer exact test, showed the following association 
between the 2 groups:  
 
1) Recurrent haemoptysis 
15 of the 20 patients who were temporised with BAE (75%) had recurrent 
haemoptysis whereas 1 of the 41 patients (2.44%) who underwent lung resection 
without BAE developed recurrent haemoptysis (p-value < 0.0001). Therefore, 
patients undergoing BAE prior to surgery have a statistically significant risk of 
recurrent haemoptysis when compared to patients having immediate surgery 
without temporising with BAE. 
. 
2) Morbidity and mortality 
In patients undergoing BAE and lung resection, there was 1 death and 2 patients 
developed a post resection empyema thoracis (5% mortality; 10% morbidity) 
compared to 2 deaths; 1 post resection empyema thoracis and 1 deep 
thoracotomy wound infection in patients’ undergoing lung resection alone (4.88% 
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mortality; 4.88% morbidity). This was not statistically significant (p-value 
0.6736). Therefore there is no statistically significant risk for complications 
(disregarding recurrent haemoptysis) if surgery is undertaken without BAE used 
as a temporising measure. 
 
3) All complications 
Complications were noted in 18 patients (90%) in the BAE prior to lung resection 
group, compared to 5 patients (12.20%) who complicated in the group who 
underwent surgery alone (p-value<0.0001). There is a statistically significant risk 
for complications if BAE is undertaken prior to lung resection. This is 
predominantly due to the high risk of recurrent haemoptysis following BAE. 
 
MORTALITY 
1) MASSIVE HAEMOPTYSIS 
a) SURGERY 
 i) TEMPORISED WITH BAE 
The only death in this group was due to fulminant septicaemia from multi-drug resistant 
Gram negative Acinetobacter grown from blood cultures.  This patient had ongoing 
massive haemoptysis despite successful BAE. Though preliminary investigations showed 
that he had AIDS (CD4 126 cells/ul which was ascertained following lung resection), a 
left pneumonectomy was undertaken as a life-saving procedure due to ongoing massive 
haemoptysis and following a second “successful” BAE. The patient required a massive 
blood transfusion and post-operative ventilation as a consequence of spill.  Death 
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occurred 10 days after surgery despite maximum medical support. Histology of the left 
lung showed mycetoma with no evidence of active TB. 
 
 ii) SURGERY WITHOUT BAE 
The first death, which occurred 9 days after surgery, was due to septic shock and 
multiple organ failure. This followed a post left pneumonectomy empyema thoracis due 
to a bronchopleural fistula. This was treated with closed-tube drainage. The patient 
eventually required mechanical ventilation. There were no significant risk factors for 
development of a bronchopleural fistula and the patient demised 3 weeks later. This 
patient had pre-operative anti-TB therapy for more than 3 months and histology of the 
left lung showed bronchiectasis and aspergilloma with no evidence of active TB. 
 
The second death occurred suddenly on day 2, following lung resection. Prior to and 
during surgery there was active haemoptysis and surgery was undertaken as life-saving 
therapy. This patient had AIDS (CD4 127 cells/ul) and was not on HAART. He was 
ventilated overnight, resuscitated after lung resection and demised on day 2 in the high 
care unit while awaiting transfer to the general ward. The aetiology of his death was 
probably aspiration as a consequence of a bronchopleural fistula, but this was merely 
speculation as a post mortem was not undertaken. This patient was on anti-TB therapy 
for a month prior to emergency lung resection. Histology confirmed active TB which was 






1) MASSIVE HAEMOPTYSIS 
a) SURGERY 
 i) TEMPORISED WITH BAE 
The first patient with a post resection empyema thoracis was HIV positive (CD4 283 
cells/ul) and underwent an emergency right upper lobectomy for recurrent massive 
haemoptysis after “successful” BAE. Intra-operatively no mycetoma-containing cavity 
was breached and histology showed bronchiectasis with no evidence of active TB. He 
was treated with open drainage and was well upon discharge. 
 
The second patient with a post resection empyema thoracis was HIV positive on HAART 
but a viral load (CD4 110 cells/ul-preoperative) was not obtained.  Elective right 
pneumonectomy was undertaken about 2 months later to allow resolution of an 
associated bronchopneumonia, treated with oral antibiotics. BAE was undertaken as a 
temporising measure and there was no recurrence of haemoptysis during the period 
prior to lung resection. She was treated with open drainage and was well at the 3 month 
follow up. Histology showed aspergilloma with no evidence of active TB. 
 
 ii) SURGERY WITHOUT BAE 
One patient developed a post right upper lobectomy empyema thoracis. Lung resection 
was undertaken due to ongoing massive haemoptysis and surgery was life-saving. This 
patient had AIDS (CD4 157 cell/ul) and was not on HAART. He was transfused with 7 
units of packed cells peri-operatively. During surgery the aspergilloma-containing cavity 
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was breached resulting in soiling of the pleural space.  Post-operatively he required a 
short period of ventilation due to hypothermia and acidosis resulting from prolonged 
surgery. The empyema thoracis was treated satisfactorily with open drainage and this 
patient was well at 3 months follow up. Histology showed bronchiectasis with no 
evidence of active TB. 
 
A deep thoracotomy wound infection occurred in a patient who underwent an 
emergency left pneumonectomy for ongoing massive haemoptysis. Pre-operatively, 
following preliminary thoracic surgical evaluation, he had a haemoglobin of 8.6g/dl, 
albumin 28g/dl, was HIV positive with a CD4 cell count of 209 cells/ul and was 
diagnosed with active TB, 4 weeks prior to surgery. Intra-operatively the patient had a 
hypoxic arrest as a consequence of a blocked double lumen endotracheal tube and 
required a very short period of cardiopulmonary resuscitation. This patient required 
ventilation for a day. He was discharged in a fortnight and at 3 months follow up his 
wound had healed and he was well. Histology of the lung showed bronchiectasis with no 










b) BRONCHIAL ARTERY EMBOLISATION 
189 patients underwent BAE as definitive therapy.   
25 patients had recurrent haemoptysis following BAE (13.23%). 
16 patients demised (8.47%). 13 patients (6.88%) died from recurrent massive 
haemoptysis (3 of these patients had failed BAE. In 2 of these procedures the catheters 
failed to engage the abnormal vessels and in 1 procedure the presence of spinal feeders 
contraindicated embolisation); 1 from contrast induced renal failure and 1 from a 
massive embolic cerebrovascular accident (CVA) following BAE. Another patient, who 
presented after a year with recurrent minor haemoptysis, following previous “successful 
BAE”, was ineligible for BAE due to HIV associated nephropathy and subsequently 
demised from poor health.  
 
2 patients developed post BAE embolic cerebrovascular accidents (CVA) (1.06%).  One 
developed a right T6 and left T8 sensory level due to spinal cord ischaemia. No spinal 
feeders were noticed during the procedure.  The other patient developed a right 
homonymous hemianopia. Spinal feeders were seen during the procedure and noted to 
be arising from the posterior intercostal vessels. 
 
24 patients had a failed BAE (12.70%). There were a total of 28 BAE procedures 
undertaken.  Of these, 16 showed spinal feeders which did not allow embolisation; 7 
procedures undertaken did not  permit catheters to engage abnormal vessels; 3 
procedures failed to show abnormal vessels despite underlying lung disease and 2 
procedures showed fistulae to the left pulmonary vein which contraindicated BAE. 
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c) MEDICAL THERAPY 
There were 32 patients in this group.  Of these, the majority included, 21 patients who 
had active or sequelar TB; 4 patients had irresectable bronchial carcinoma (confirmed 
either on sputum cytology or fine needle aspiration cytology and who were referred to 
the Department of Oncology for further treatment); 3 patients had a bronchopneumonia; 
1 patient presented with cor pulmonale and in 3 patients no source of haemoptysis could 
be found despite detailed thoracic surgery and ear, nose and throat (ENT) investigations.  
 
Recurrent haemoptysis occurred in 6 patients (18.75%). Of these, 5 patients had 
recurrent massive haemoptysis and demised (15.63%).  The other patient had recurrent 
minor haemoptysis but refused any intervention (3.13%)   
 
There were 7 deaths (21.88%), 5 of which resulted from recurrent massive haemoptysis, 
1 from right heart failure (cor pulmonale) and 1 from generalised ill health as a 











GROUP 2: MINOR HAEMOPTYSIS 
a) SURGERY 
An analysis comparing the occurrence of recurrent haemoptysis following treatment, 
morbidity, mortality and all complications (including recurrent haemoptysis, morbidity 
and mortality) between those patients treated with BAE prior to surgery and those 
treated with surgery alone using the Fischer exact test, showed the following association 
between the 2 groups:  
 
1) Recurrent haemoptysis 
7 of the 8 patients who were temporised with BAE (87.50%) had recurrent 
haemoptysis. None of the 44 patients who underwent lung resection alone, 
developed recurrent haemoptysis (p-value < 0.0001). Therefore, patients 
undergoing BAE prior to surgery were shown to have a statistically significant 
risk of recurrent haemoptysis following BAE, when compared to patients having 
emergency surgery alone. 
 
2) Morbidity and mortality 
There were no deaths or surgical complications other than recurrent haemoptysis 
in patients who underwent BAE prior to lung resection.  Though there were no 
deaths in patients who underwent lung resection alone, 2 patients developed a 
post resection bronchopleural fistula and 1 patient developed a post resection 
empyema thoracis (6.82% morbidity).  
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This was not statistically significant (p-value 1.0000).  Therefore there is no 
statistically significant risk factor for complications, if surgery is undertaken 
without BAE. 
 
Both patients who complicated with a bronchopleural fistula had elective surgery 
for minor haemoptysis and were on anti-TB therapy preoperatively. Histology for 
one of these patients suggested active TB whilst the other showed features of 
sequelar TB only. There were no other significant risk factors for a 
bronchopleural fistula in both patients, suggesting that flawed surgical technique 
was the probable cause.  Successful surgical repair was undertaken in both 
patients using a muscle flap. 
 
The third patient complicated with a post-lobectomy empyema thoracis. 
Following elective surgery, re-exploration for excessive post-operative 
haemorrhage was undertaken on the same day. Bleeding from a bronchial artery 
was seen and stopped.  The patient required a blood transfusion with 6 units of 
packed cells. Histology of the left upper lobe showed bronchiectasis and 
aspergilloma with no evidence of active TB. An empyema thoracis developed 
within 2 weeks. A fortnight later, a decortication of the lung did not achieve a 
satisfactory result and an open drainage using a cut malecot catheter draining 
into stoma bag was opted for.  After 6 months, the malecot catheter was removed 




3) All complications 
Complications were noted in 7 patients (87.50%) in the group who was 
temporised with BAE prior to surgery,  compared to 3 patients (6.82%) who 
complicated in the group who underwent surgery alone (p-value<0.0001). 
Therefore there is a statistically significant risk for complications if BAE is 
undertaken prior to lung resection. This is predominantly due to the high risk of 



















b) BRONCHIAL ARTERY EMBOLISATION 
75 patients in this group underwent BAE as definitive therapy.  
Recurrent haemoptysis occurred in 11 patients (14.67%). There were 2 deaths (2.67%) 
and both were as a consequence of recurrent massive haemoptysis.  These fatal massive 
episodes occurred within 1 week and 2 months respectively of BAE.  
The other 9 patients with recurrent haemoptysis had minor episodes of haemoptysis. 
Other complications included 1 patient who developed a left sided embolic 
cerebrovascular accident (CVA), following BAE (1.33%).  
 
8 patients had failed BAE (10.67%). There were a total of 9 BAE procedures undertaken.  
Of these, 3 showed spinal feeders contraindicating embolisation; 3 procedures did not 
permit catheters to engage abnormal vessels and 3 procedures failed to show abnormal 













c) MEDICAL THERAPY 
There were 94 patients in this group.  Of these, the majority included 56 patients with 
active or sequelar TB; 20 patients with irresectable bronchial carcinoma (confirmed 
either on sputum cytology or fine needle aspiration cytology and referred to the 
Department of Oncology for further treatment); 15 patients with bronchopneumonia; 1 
patient with an eroding thoracic aortic aneurysm and in 2 patients no source of 
haemoptysis could be found despite detailed thoracic surgery and ENT investigations.  
 
Recurrent haemoptysis occurred in 7 patients (7.45%), all of which were due to active or 
sequelar TB. 2 patients had recurrent massive haemoptysis and demised. 5 patients had 
recurrent minor haemoptysis.   
 
There were 9 deaths (9.57%), 2 of which resulted from recurrent massive haemoptysis 
(2.13%), 4 from irresectable bronchial carcinoma and 3 from generalised ill health as a 











It is indisputable that in patients presenting with haemoptysis, lung resection is usually 
curative and BAE is a temporising measure. Simply stated, surgery is superior to BAE as 
a treatment option in these patients. Despite this, BAE has been advocated prior to 
surgery in all patients presenting with haemoptysis. Surprisingly, this also includes 
patients presenting with active massive haemoptysis who require little or no pre-
operative preparation. This treatment strategy was borne from the high morbidity and 
mortality previously associated with emergency lung resection in patients presenting 
with massive haemoptysis. However, these results may have been as a consequence of 
poor surgical selection. With appropriate detailed pre-operative evaluation, this review 
has shown similar outcomes for both emergency and elective lung resection for massive 
haemoptysis without pre-operative BAE when compared to BAE prior to lung resection. 
BAE is a temporising measure which even if “successfully” undertaken still exposes these 
patients to recurrent and possible fatal haemoptysis. Therefore, by undertaking 
emergency lung resection without BAE in  appropriate patients, the unnecessary risk of 
recurrent massive haemoptysis and possible death is avoided. This is contrary to current 
treatment methods for these patients. 
 
Recurrent haemoptysis following BAE 
Recurrent haemoptysis following BAE occurs in up to 20%-45% of patients at 1 month 
[Fernando, HC., et al; Mal, H., et al; Andrejak, C., et al].  This may be due to incomplete 
occlusion of the feeding vessels, recanalisation of previously embolised vessels, the 
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development of new collaterals or inadequate treatment of the underlying disease 
[Fernando, HC., et al; Mal, H., et al; Hankanson, E., et al]. 
However, this high recurrence rate may be extremely hazardous since surgery may have 
to be undertaken in actively bleeding patients in whom BAE has failed. This poses an 
increased risk of soiling of the normal lung leading to an increased mortality even if lung 
resection is not undertaken. 
 
In this review, 15 patients (75%) presenting with massive haemoptysis who were 
temporised with BAE prior to lung resection, had recurrent haemoptysis following BAE 
despite being suitable surgical candidates upon admission. Of these, 7 patients (46.67%) 
had bouts of recurrent massive haemoptysis following BAE. This necessitated emergency 
surgery.   Furthermore of the 8 patients in this review, who underwent BAE for minor 
haemoptysis and who were deemed feasible for lung resection prior to BAE, 5 had 
recurrent haemoptysis (62.5%). Of these, 1 (20%) had recurrent massive haemoptysis 
requiring emergency surgery.  This study has not shown significant morbidity and 
mortality associated with lung resection alone, albeit in selected patients presenting with 
massive haemoptysis. Therefore it can be reasonably deduced that BAE undertaken pre-
operatively places these patients at an unnecessary risk of recurrent massive 
haemoptysis and possible death. 
 
Recurrent haemoptysis following BAE is much higher compared to that following 
surgery. Lung resection is curative because the focus of the haemoptysis is excised. BAE, 
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on the other hand, is a temporising measure because it deals with the sequelae of 
pulmonary disease i.e. the pathological blood vessels. 
 
Outcomes of Surgery for Haemoptysis 
Patients with massive haemoptysis who are eligible for surgery, but who are treated 
medically, have a 78-85% [Knott-Craig, CJ., et al] mortality as a consequence of massive 
haemoptysis. This risk of death decreases to 10-35% if surgery is undertaken [Knott-
Craig, CJ., et al; Andrejak, C., et al; Shigemura, N., et al].   
Recurrent haemoptysis following surgery for massive haemoptysis may occur in up to 
5% [Andrejak, C., et al]. This may be due to incomplete excision of the underlying 
diseased lung, progression or reactivation of disease or development of new lung 
pathology. In our series, 1of 41 (2.44%) patients had recurrent haemoptysis following 
emergency surgery for massive haemoptysis. This was attributed to recurrent primary 
pulmonary tuberculosis which was successfully treated with anti-TB therapy. 
 
From Table 3 it should be noted that the major outcome that differs between surgery 
alone versus BAE plus surgery is recurrent haemoptysis.  Though morbidity and 
mortality between these 2 groups were insignificant in our preliminary data, a 
prospective study is deemed feasible further analyse the 2 groups. 
This series assessed all-cause mortality. Analysis has shown a mortality of less than 5% 
in all patients undergoing emergency surgery for massive haemoptysis without pre-
operative BAE, and about 5% in those patients undergoing surgery for massive 
haemoptysis following BAE.  The difference in mortality between these 2 groups was not 
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significant in our preliminary data. This questions the previously held belief that BAE 
undertaken prior to lung resection improves outcomes especially in those patients 
presenting with active massive haemoptysis and suggests the necessity of a prospective 
study to further analyse morbidity and mortality. 
 
In this series, complications of lung resection for massive haemoptysis following BAE 
included: 1 death (1/20; 5%), as a consequence of respiratory failure due to a post-lung 
resection bronchopneumonia and 2 patients (2/20; 10%) who developed a post-
resection empyema thoracis.   
 
Surgery for massive haemoptysis without BAE resulted in the following complications: 2 
deaths (2/41; 4.88%) both as a consequence of respiratory failure exacerbated by post-
resectional bronchopleural fistulae and 1 patient (1/41; 2.44%) who developed a post-
resectional empyema thoracis.  
 
These figures compare favorably to the current complication rates worldwide, which 
show an 18-30% occurrence of post-operative bronchopleural fistulae and post-
resectional empyema thoraces in patients undergoing surgery for massive haemoptysis 
following BAE [Shigemura, N., et al]. Andrejak et al. showed a 5-11% occurrence of post-
resection bronchopleural fistulae in patients undergoing emergency lung resection with 
active haemoptysis. This figure increased to 20% for planned resections i.e. patients with 
massive haemoptysis who were successfully temporised with BAE. Though not 
mentioned, this may be due to emergency lung resection undertaken in patients with 
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recurrent massive haemoptysis following BAE. These patients usually spill into the 
bronchial tree and surgery undertaken under these circumstances is associated with a 
higher risk of complications. 
 
In this review, there were no complications in the group with minor haemoptysis who 
were temporised with BAE prior to surgery. 2 patients (2/44; 4.55%) in the group who 
had surgery for minor haemoptysis without BAE developed post-resection 
bronchopleural fistulae. 
 
There was no mortality in our series in patients undergoing lung resection for minor 
haemoptysis even in patients having recurrent haemoptysis following BAE. 
 
The surgical mortality from current experience worldwide is significantly higher than in 
this series. This may be due to suboptimal pre-operative evaluation, patient selection 
and timing of surgery in other centres.  
This study suggests that emergency lung resection, without BAE, as the initial treatment 
modality, in appropriately selected patients presenting with massive haemoptysis and 
radiologically localised disease may be valid. This preliminary data would require a 
prospective study to confirm these suggestions. Nevertheless, at present, in our 
institution, all patients presenting with massive haemoptysis who are deemed suitable 
for lung resection, now undergo emergency surgery without the delay of BAE in order to 
avoid the risk of recurrent massive haemoptysis and soiling of the bronchial tree. 
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Multi-variable logistic regression analysis (Table 6) is limited in this study since the 
events per variable for other factors were too few. This preliminary data once again       
re-enforces the need for a prospective study. 
 
HIV and Surgery 
The literature deals extensively with surgery in the HIV positive patient. It is possible 
that HIV status may be affect recurrent haemoptysis following surgical intervention. In a 
post hoc analysis, the influence of HIV status on the treatment outcomes of the surgery 
alone group and the surgery and BAE group were analysed. 
Following multivariable analysis, HIV status was not found to be significantly associated 
recurrent haemoptysis in both surgical groups i.e. surgery alone and BAE with surgery.  
 
Outcomes of BAE  
It is worthwhile repeating that, though BAE is essentially a temporising measure, it has 
to be regarded as definitive in those patients in whom lung resection is not feasible. 
Studies show that BAE results in immediate cessation of haemoptysis in up to 77% [Mal, 
H., et al].   
 
In our series, the rate of recurrent haemoptysis following treatment with BAE alone 
occurred in 13.23% (25/189) of patients presenting with massive haemoptysis and 
14.67% (11/75) of patients presenting with minor haemoptysis. This compares 
favorably with current figures worldwide. However, these patients in this study were not 
eligible for lung resection and were discharged within 48 hours following BAE. In 
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addition, follow up of patients treated using non-surgical therapies was extremely poor. 
Besides the immediate outcomes of BAE, the short and long term outcomes of BAE in this 
study could therefore not be accurately reviewed. Therefore there is a bias in this sample 
since follow up was inadequate. 
Common complications of BAE include: chest pain (24%-91%), dysphagia (0.7%-18.2%) 
subintimal dissection of the aorta or the bronchial arteries (1%–6.3%). As stated 
previously, the most disastrous complication of BAE is spinal cord ischaemia due to the 
inadvertent occlusion of spinal arteries [Mal, H., et al]. The prevalence of spinal cord 
ischemia after BAE is reported to be 1.4%–6.5%.   
Complications of BAE in our series of 264 patients for both massive (189 patients) and 
minor (75 patients) haemoptysis included 1 patient with spinal cord ischaemia 
(demised), 2 patients with embolic strokes and 1 patient with contrast induced renal 
failure (demised). 
 
13% of patients have non-bronchial collaterals as a cause of haemoptysis. Bleeding from 
non-bronchial collateral arteries should be suspected with radiological evidence of 
pleural thickening. Another important cause of failed BAE may result from 
vasoconstriction of the bronchial arteries especially when intravenous vasoconstrictors 
administered prior to BAE. 
 
In our study, failed BAE occurred in 24 patients with massive haemoptysis. Of these, 8 
patients had spinal feeders which contraindicated embolisation.  
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8 patients with minor haemoptysis had failed BAE. 2 of these patients had spinal feeders 
which contraindicated embolisation.  
Though not considered an absolute contraindication, spinal feeders, can in experienced 
hands, be superselected and pathological vessels embolised using microcatheters. 
 
Haemoptysis may occur from the pulmonary artery system in 5% of cases.  In this 
review, this was only investigated if a pulmonary arteriovenous malformation was 
suspected. This did not include scenarios where despite the presence of haemoptysis in 
the presence of underlying pulmonary disease, no pathological systemic arterial vessels 
were identified as the source. This may be catastrophic in patients with massive 
haemoptysis originating from the pulmonary arterial system. As stated previously, in this 
instance, emergency surgery, if feasible is the only form of definitive therapy (BAE is 
contraindicated). Unfortunately, lung resection is rarely emergently undertaken in this 
instance, since the diagnosis is difficult and often not considered as the aetiology of the 
haemoptysis.   
Patients with mycetoma-containing cavitatory disease and extensive pleural disease are 
thought to have a higher risk of recurrent bouts of haemoptysis despite BAE or medical 
therapy. 
 
Outcomes of Medical Therapy 
In our series, patients treated medically also showed low rates of recurrent haemoptysis. 
Those with massive haemoptysis showed a recurrence rate of 18.75% (6/32) and 7.45% 
(7/94) in those with minor haemoptysis.   
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The low rate of recurrent haemoptysis following medical therapy is attributed to poor 
follow up, resulting once again in a bias sample. 
Medical treatment (which may include antibiotics or radiotherapy based on the probable 
aetiology) for haemoptysis is only undertaken if BAE has failed (usually technical) or 
lung resection is not deemed feasible. This is especially so for patients with massive 
haemoptysis.  
 
Of the 94 patients in our series treated medically for minor haemoptysis, 7 had recurrent 
haemoptysis. 2 of these patients had massive bouts of haemoptysis and demised. All 7 
patients with recurrent haemoptysis had active or sequelar TB and BAE was not 
attempted in any of them.  Therefore, patients with active or sequelar TB, presenting 
with minor haemoptysis and who are ineligible for curative lung resection, BAE is the 
treatment of choice. This is especially so if radiological investigations suggests a high risk 
for recurrent massive haemoptysis. 
 
Outcomes of Surgery in patients with Active Pulmonary Tuberculosis  
41 of 113 patients, who underwent lung resection, either electively or emergently for 
massive or minor haemoptysis, had active pulmonary TB confirmed either pre-
operatively (usually on sputum analysis for acid-fast bacilli) or on TB analysis of the 
resected lung (histology or TB microscopy and culture).  Of the 3 patients who died 
following lung resection, 2 patients had a bronchopleural fistula and only 1 of these 
patients was found to have active TB.  
73 
 
2 patients were treated with open drainage for a post lung resection bronchopleural 
fistula, 1 of which had active tuberculosis. 
 
4 patients developed a post lung resection empyema thoracis. None of these patients had 
active TB following investigations for TB.  
 
1 patient who developed a deep thoracotomy wound infection also did not show 
evidence of active TB following investigations for TB. 
In summary, of the 41 patients with active TB, 2 patients had surgical complications. Of 
the 72 patients with no evidence of active TB, 8 patients had surgical complications.  
 
In our study, active TB is not a statistically significant risk factor for complications 
following lung resection for patients presenting with haemoptysis. This includes patients 
presenting with active massive haemoptysis who require emergency lung resection. 
 
Post Lung Resection Empyema Thoraces and Bronchopleural Fistulae 
The left bronchus syndrome which as a consequence of the more horizontal plane of the 
left main bronchus, the decreased peri-bronchial space and the fact that the left main 
bronchus is 15% narrower, attempts to explain why  left sided disease is more common. 
This was common to this review as well. The commonest operation was that of a left 
upper lobectomy followed by a left pneumonectomy.  
One of the risk factors for a post-resection empyema thoracis or a post-resection 
bronchopleural fistula (BPF) includes a right pneumonectomy. However our series did 
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not show a significant association between a right pneumonectomy and post-resection 
empyema thoraces or a BPF. 
All bronchial stumps were closed with interrupted Vicryl ® (Johnson and Johnson) 
absorbable sutures.  Reinforcing the bronchial stump with a muscle flap was rarely used. 
“Salvage Surgery” 
Though not routinely recommended the concept of ‘salvage surgery’ is proposed in 
patients with extensive bilateral lung disease with symptoms of recurrent haemoptysis, 
despite numerous “successful” interventions with BAE. In this category of patients, 
despite extensive bilateral disease, the radiological investigations may suggest that the 
haemoptysis may be arising from a localised area of the diseased lung (e.g. cavity with 
mycetoma in a lobe). This should be confirmed by rigid bronchoscopy. Thereafter, if 
following detailed routine evaluation, lung resection is deemed suitable, this may be 
undertaken with the intention of cure. Though our series only included 2 such patients, 
this form of management should be considered, since surgery may be life-saving. 
 
Study Limitations 
The major limitation of our study was patient follow up. It should realised that any study 
undertaken in an indigent population, which includes the vast majority of this study 
group, poor follow up, especially if patients are well, is inevitable. Inadequate transport 
facilities required to cover vast distances to reach a hospital and poverty are the main 
reasons for this. However, the main focus of this study was on patients presenting with 
haemoptysis who underwent lung resection with and without pre-operative BAE. The 
limitation of patient follow up did not affect this study group. All patients who 
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underwent successful lung resection were followed up for a minimum of 6 months and 
those who complicated with recurrent haemoptysis, bronchopleural fistulae or post-
resection empyema thoraces were followed up beyond 6 months. 
 
All patients treated with BAE alone were discharged within 2 days of treatment. All 
patients treated with medical therapy were discharged with 5 days of admission once 
assessment for other treatment modalities was complete. 
It then stands to reason, that this retrospective study was not suitable to evaluate 
treatment outcomes of both BAE and medical therapy  since both inpatient stay was 
short and patient follow up was very poor. The results tabulated in table 5 are therefore 
extremely biased.  Furthermore, as we are a surgical unit with limited state resources, 
our primary concerns were patients who underwent lung resection. The other categories 
of patients are capably managed at base hospitals and for the overwhelming majority did 
not require further thoracic surgical opinions. It stands to reason that follow up of these 
patients is relatively non-existent. 
 
Nevertheless, other studies have extensively evaluated BAE and medical therapy alone 
and the superiority of the addition of lung resection is not in dispute. It is for this reason 
this study focuses on surgery alone versus surgery following BAE. It is necessary to 
reiterate that all previous studies advocate BAE as a preliminary treatment method prior 
to lung resection even if upon admission patients are suitable for emergency lung 
resection. This is despite the fact that the risk of a possible fatal bout of recurrent 
haemoptysis following BAE is significantly higher than if lung resection is undertaken. 
76 
 
It is possible that the BAE plus surgery group had more chronic and complex disease 
which could have resulted in worse outcomes when compared to the surgery alone 





















This retrospective review implies that all patients presenting with localised disease and 
massive haemoptysis, who are deemed suitable for surgery, should undergo emergency 
lung resection without undertaking BAE as a temporising measure. This is so, since this 
preliminary data shows a significant difference in recurrent haemoptysis if surgery is 
undertaken without BAE as a temporising measure. The previous belief of not 
undertaking emergency lung resection in patients with active massive haemoptysis 
because of the associated prohibitively high morbidity and mortality was not evident in 
our series. Therefore, BAE as a temporising measure in patients who are suitable for 
surgery should not be undertaken since delayed lung resection places the patient at an 
unnecessary risk of possible fatal recurrent massive haemoptysis. 
 
Though prospective studies are required, it is suggested that BAE be reserved for 
patients who refuse or are deemed unsuitable for surgery. 
 
Furthermore, it is also suggested that medical therapy alone should probably only be 
implemented if surgery or BAE is not feasible. This is especially so in patients with minor 
haemoptysis as a consequence of active or sequelar TB where there is radiological 
evidence suggestive of a high risk of massive haemoptysis. Patients presenting with 
minor haemoptysis due to other causes may be treated according to the possible 
aetiology of the underlying disease i.e. recurrent minor haemoptysis due to irresectable 
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